CO2024000581A2 - Comprimido que comprende una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico - Google Patents

Comprimido que comprende una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico

Info

Publication number
CO2024000581A2
CO2024000581A2 CONC2024/0000581A CO2024000581A CO2024000581A2 CO 2024000581 A2 CO2024000581 A2 CO 2024000581A2 CO 2024000581 A CO2024000581 A CO 2024000581A CO 2024000581 A2 CO2024000581 A2 CO 2024000581A2
Authority
CO
Colombia
Prior art keywords
tablet
hydroxybenzoyl
amino
salt
caprylic acid
Prior art date
Application number
CONC2024/0000581A
Other languages
English (en)
Inventor
Thomas Kvistgaard Vilhelmsen
Isabell Vargas Christensen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of CO2024000581A2 publication Critical patent/CO2024000581A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a un comprimido que comprende una sal del ácido N-(8-(2- hidroxibenzoil)amino)caprílico. La invención se refiere además a procesos para la preparación de dicho comprimido, y a su uso en medicina.
CONC2024/0000581A 2021-07-15 2024-01-24 Comprimido que comprende una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico CO2024000581A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21185861 2021-07-15
PCT/EP2022/069704 WO2023285580A1 (en) 2021-07-15 2022-07-14 Tablet comprising a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid

Publications (1)

Publication Number Publication Date
CO2024000581A2 true CO2024000581A2 (es) 2024-02-05

Family

ID=76942907

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0000581A CO2024000581A2 (es) 2021-07-15 2024-01-24 Comprimido que comprende una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico

Country Status (12)

Country Link
US (1) US20240335388A1 (es)
EP (1) EP4370102A1 (es)
JP (1) JP2024525377A (es)
KR (1) KR20240036563A (es)
CN (1) CN117979958A (es)
AU (1) AU2022312702A1 (es)
CA (1) CA3223236A1 (es)
CL (1) CL2023003974A1 (es)
CO (1) CO2024000581A2 (es)
IL (1) IL309535A (es)
MX (1) MX2024000768A (es)
WO (1) WO2023285580A1 (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
EP1149066B1 (en) 1999-02-05 2005-11-09 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
AU2001275231A1 (en) 2000-06-02 2001-12-11 Emisphere Technologies, Inc. Method of preparing salicylamides
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
AU2007293916B2 (en) 2006-09-07 2011-02-03 Emisphere Technologies, Inc. A process for the manufacture of SNAC (salcaprozate sodium)
EP3741359A1 (en) 2008-08-18 2020-11-25 Entera Bio Ltd. Methods and compositions for oral administration of proteins
PT2651398T (pt) 2010-12-16 2018-03-09 Novo Nordisk As Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
CN104203221A (zh) * 2012-03-22 2014-12-10 诺和诺德A/S（股份有限公司） 包含递送剂的组合物及其制备
EP2827885B1 (en) * 2012-03-22 2018-08-15 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
AU2014261336B2 (en) 2013-05-02 2019-02-28 Novo Nordisk A/S Oral dosing of GLP-1 compounds
SG11202006595RA (en) * 2018-02-02 2020-08-28 Novo Nordisk As Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
CA3144618A1 (en) * 2019-08-07 2021-02-11 Novo Nordisk A/S Solid compositions comprising an egf(a) derivative and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN114340655A (zh) * 2019-09-02 2022-04-12 诺和诺德股份有限公司 生产包含glp-1肽的片剂的方法

Also Published As

Publication number Publication date
CL2023003974A1 (es) 2024-08-02
CN117979958A (zh) 2024-05-03
IL309535A (en) 2024-02-01
JP2024525377A (ja) 2024-07-12
US20240335388A1 (en) 2024-10-10
MX2024000768A (es) 2024-02-12
AU2022312702A1 (en) 2024-01-18
EP4370102A1 (en) 2024-05-22
KR20240036563A (ko) 2024-03-20
WO2023285580A1 (en) 2023-01-19
CA3223236A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
CO2020009997A2 (es) Composiciones sólidas que comprenden un agonista de glp-1, una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico y un lubricante
CL2020002797A1 (es) Composiciones sólidas que comprenden un agonista de glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
CO2022000578A2 (es) Composiciones sólidas que comprenden un agonista del glp-1, un inhibidor del sglt2 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
ECSP22012826A (es) Inhibidores de parp1
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
CL2020000122A1 (es) Métodos de tratamiento para la fibrosis quística.
CO2022005904A2 (es) Composiciones sólidas que comprenden un inhibidor de pcsk9 y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico
CO2022000575A2 (es) Composiciones sólidas que comprenden un derivado de egf(a) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico
EA202091318A1 (ru) Препарат, содержащий аденовирус группы b
CL2010000434A1 (es) Uso de una composicion farmaceutica que comprende vitamina b12 y acido n-(8-(2-hidroxibenzoil)animo) caprilico o sus sales para preparar un medicamento util en el tratamiento de la deficiencia de vitamina b12; composicion farmaceutica.
BR112018068565A2 (pt) combinações de inibidores de lsd1 para uso no tratamento de tumores sólidos
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
EA201791350A9 (ru) Радиофармацевтические комплексы
PH12020551841A1 (en) Stable pharmaceutical formulation
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1
BR112019009029A2 (pt) anticorpos anti-bag3 em combinação com inibidores do ponto de verificação imune para uso terapeutico
PE20180691A1 (es) Variantes de il-37
CO2017008426A2 (es) Ácido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4- [(5-metiloxazol-2-carbonil)amino]pentanoico
CO2024000581A2 (es) Comprimido que comprende una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
CL2017003465A1 (es) Uso combinado de bumetanida con ácido valproico o una de sus sales farmacéuticamente aceptables para restablecer la homeostasis de cl- y con ello, permitir la preparación de un fármaco efectivo en el tratamiento de la epilepsia, y especialmente, en el tratamiento de la epilepsia refractaria.
ES2475942B1 (es) Composición farmacéutica de citrato de sildenafilo en forma de solución acuosa
CO2024000463A2 (es) Forma polimórfica a de n-(8-(2- hidroxibenzoil)amino)caprilato de sodio
CY1120767T1 (el) Συνθεσεις glp-1 πεπτιδιων και παρασκευη αυτων
AR122297A1 (es) Composiciones sólidas que comprenden un agonista del glp-1, un inhibidor del sglt2 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico